Compare TransMedics Group Inc (TMDX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Thomson Reuters Corp — how do they compare? TransMedics Group Inc trades at $86.49 (market cap $3.10B), while Thomson Reuters Corp trades at $101.56 (market cap $45.38B). The key difference: Thomson Reuters Corp is far larger — about 14.6× TransMedics Group Inc's market cap, and Thomson Reuters Corp pays a 2.5% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | TRI | |
|---|---|---|
Market Cap | $3.10B | $45.38B |
Sector | Technology | Industrials |
52-Week High | $150.42 | $178.77 |
52-Week Low | $61.99 | $76.55 |
Enterprise Value | $3.49B | $48.00B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Thomson Reuters (TRI) trades at $104.36, up 2.48% today, with a bullish technical signal and strong support at $102. The company reported Q2 2026 earnings of $0.99 per share, beating estimates, and raised full-year revenue guidance. Fundamentals show robust profitability with a 21.22% net income margin and 8% organic revenue growth, though cash flow trends indicate recent net outflows.
Outlook remains positive driven by AI product adoption and recurring revenue growth, but risks include execution on tech transitions and competitive pressures. Analysts project a 29.8% upside to the $124 high target, with a majority recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
